衰老与心力衰竭：人口统计学变化及对老年患者治疗的影响。
Aging and heart failure: changing demographics and implications for therapy in the elderly.
机构信息
Division of Cardiology, Department of Medicine and Cardiovascular Research Group, Faculty of Medicine, 2C2 Walter MacKenzie Health Sciences Centre, University of Alberta, Edmonton, AB T6G 2R7, Canada.
出版信息
Heart Fail Rev. 2010 Sep;15(5):401-5. doi: 10.1007/s10741-010-9164-8.
The elderly population (age > or =65) is increasing and with it morbidity, hospitalizations, costs and mortality due to heart failure (HF). HF is a progressive disorder that is superimposed on an on-going aging process. The two broad categories of HF, HF with left ventricular (LV) systolic dysfunction or low ejection fraction (HF/low-EF) and HF with preserved ejection fraction (HF/PEF) are equally prevalent in the elderly. Trials of therapy for HF/low-EF in primarily non-elderly patients showed mortality benefit in elderly patients. In contrast, trials for HF/PEF have not shown mortality benefit in elderly or non-elderly patients. HF pharmacotherapy in the elderly is challenging and needs to be individualized and consider several aging-related changes. More research into the biology of aging and more clinical trials in elderly patients are needed to improve morbidity and mortality in elderly HF patients.
老年人口（年龄≥65 岁）不断增加，随之而来的是心力衰竭（HF）发病率、住院率、医疗费用和死亡率的增加。HF 是一种进行性疾病，它叠加在持续的衰老过程之上。HF 的两个主要类别，即左心室（LV）收缩功能障碍或射血分数降低的 HF（HF/low-EF）和射血分数保留的 HF（HF/PEF），在老年人中同样普遍。主要针对非老年患者的 HF/low-EF 治疗试验表明，老年患者有生存获益。相比之下，HF/PEF 的试验并未显示老年或非老年患者有生存获益。HF 在老年患者中的药物治疗具有挑战性，需要个体化，并考虑与衰老相关的几个变化。需要更多针对衰老生物学的研究和更多针对老年患者的临床试验，以改善老年 HF 患者的发病率和死亡率。
Zotero 插件